Clinical Trials Logo
  1. Home
  2. Parkinson Disease Psychosis
  3. NCT04292223

Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

Parkinson Disease Psychosis Clinical Trial

Official title:
A 16-Week Open-Label Study of the Effects of Treatment With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

Clinical Trial Summary

To assess the effect of pimavanserin on the activities of daily living in subjects with Parkinson's Disease Psychosis

Clinical Trial Description

This study will be conducted as a 16-week, multi-center, single-arm, open-label study. Pimavanserin will be administered at a dose of 34 mg to approximately 50 subjects with PDP ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04292223
Study type Interventional
Source ACADIA Pharmaceuticals Inc.
Contact
Status Completed
Phase Phase 4
Start date February 10, 2020
Completion date April 26, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05824728 - Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis Phase 2
Terminated NCT03152292 - The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study
Withdrawn NCT05344365 - A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis Phase 2
Recruiting NCT05357612 - Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases Phase 4
Completed NCT06450184 - Bioequivalence Study of Pimavanserin 34 mg Capsule Phase 1
Completed NCT02969369 - A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis Phase 2
Not yet recruiting NCT05995782 - A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418 Phase 1
Recruiting NCT04579887 - Presence Hallucination in Parkinson's Disease N/A
Recruiting NCT04592965 - Hallucinations in Parkinson's Disease N/A
Completed NCT05240339 - Characterization and Progression of Minor Phenomena in Parkinson's Disease (PD)
Recruiting NCT03661125 - SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis Early Phase 1